Furthermore, rats in the CIS group had a higher expression of SHIP2 mRNAs than rats in the control group (Figure 5c, p < 0.001), and after Xiaoyaosan treatment, the level of SHIP2 mRNA was decreased (Figure 6c, p < 0.05), but there was no significant change in the rosiglitazone group (Figure 5c, p > 0.05). The gene discussed is INPPL1; the disease is in situ carcinoma.